6-methyl-5-(4-nitrobenzoyl)-2(1H)-pyridinone | 55130-67-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 6-methyl-5-(4-nitrobenzoyl)-2(1H)-pyridinone
• 英文别名: 6-methyl-5-(4-nitrobenzoyl)-1H-pyridin-2-one
• CAS: 55130-67-1
• 化学式: C₁₃H₁₀N₂O₄
• 分子量: 258.233
• InChiKey: CKZLTJMJVJAFLF-UHFFFAOYSA-N

物化性质

• 沸点：
  499.1±45.0 °C(Predicted)
• 密度：
  1.356±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  92
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-methyl-5-(4-nitrobenzoyl)-2(1H)-pyridinone 在 乙酸铵 、 盐酸 、 N-溴代丁二酰亚胺(NBS) 、 过氧化氢苯甲酰 、 硫酸 、 氨 、 tin(ll) chloride 、 sodium nitrite 、 三氯氧磷 作用下， 以 四氯化碳 为溶剂， 反应 61.0h， 生成 3-bromo-5-(4-hydroxyphenyl)-1,6-naphthyridin-2-amine
  参考文献：
  名称：

  Novel and Potent Adenosine 3',5'-Cyclic Phosphate Phosphodiesterase III Inhibitors: Thiazolo[4,5-b][1,6]naphthyridin-2-ones

  摘要：

  The transformation of 3-bromo-1,6-naphthyridin-2(1H)-ones 8 to thiazolo[4,5-b][1,6]naphthyridin-2(1H)-ones 12 resulted in a 2-9-fold increase in cAMP phosphodiesterase (PDE) III inhibitory potency. Unlike the secondary binding sites on the cAMP PDE III isozyme which interact with the methyl group of milrinone (2) and CI-930 (4), the site which interacts with the 5-substituents of 1,6-naphthyridin-2(1H)-ones and the 8-substituents of thiazolo[4,5-b][1,6]-naphthyridin-2(1H)-ones 12 is able to accommodate a diverse group of substituents which have different steric and electronic requirements.

  DOI：

  10.1021/jm00014a007
• 作为产物：
  描述：

  1-(4-硝基苯基)丁烷-1,3-二酮 在 ammonium acetate 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 29.0h， 生成 6-methyl-5-(4-nitrobenzoyl)-2(1H)-pyridinone
  参考文献：
  名称：

  Novel cAMP PDE III inhibitors: 1,6-naphthyridin-2(1H)-ones

  摘要：

  Two series of medorinone (3) analogs were prepared by modifications at C(2) and C(5). The C(2)-series was prepared from 2-chloro-5-methyl-1,6-naphthyridine (4) by replacement of the chloro group with various nucleophiles. The C(5)-series was prepared from 5-acyl-6-[2-(dimethylamino)ethenyl]-2-(1H)-pyridinone (11), 5-bromo-1,6-naphthyridin-2(1H)-one (17), and 1,3-diketones 19 and 27. 1,6-Naphthyridin-2(1H)-ones are novel inhibitors of cAMP PDE III. Modification of the carbonyl group of 3 or N-methylation at N(1) resulted in a dramatic loss of enzyme activity. Absence of the C(5)-methyl group of medorinone (3) or its shift to C(3) or C(7) also resulted in reduced activity. Substitution at C(3) also diminished activity. However, substitution at C(5) by a wide variety of substituents led to improvement of enzyme activity and several C(5)-substituted analogs were more potent than milrinone.

  DOI：

  10.1021/jm00104a012

文献信息

• 5-(Phenyl)-1,6-naphthyridin-2(1H)-ones, their cardiotonic use and
  申请人：Sterling Drug Inc.

  公开号：US04560691A1

  公开（公告）日：1985-12-24

  1-R-5-Ar-1,6-naphthyridin-2(1H)-ones (I) or salts thereof, where R is hydrogen or methyl, and Ar is phenyl or phenyl substituted by methyl, ethyl, methoxy, ethoxy, hydroxy, amino, acetylamino, methanesulfonylamino, bromo, chloro, fluoro, cyano or carbamyl are useful as cardiotonic agents and corresponding compounds where Ar is nitrophenyl are useful as intermediates. Also shown as intermediates, are 5-(Ar--CO)-6-[2-(di-lower-alkylamino)-ethenyl]-2(1H)-pyridinones (II) or salts thereof, where Ar is phenyl or phenyl substituted by methyl, ethyl, methoxy, ethoxy, bromo, chloro, fluoro, cyano or nitro and 5-(Ar--CO)-6-methyl-2(1H)-pyridinones (III) where Ar is phenyl or phenyl substituted by methyl, ethyl, methoxy, ethoxy, bromo, chloro, fluoro, hydroxy, cyano or nitro; said compounds (III) where Ar is phenyl or hydroxyphenyl also are useful as cardiotonic agents. Processes for preparing the compounds of formulas I, II and III are shown.

  1-R-5-Ar-1,6-萘啶并[2(1H)-酮]（I）或其盐，其中R为氢或甲基，Ar为苯基或甲基、乙基、甲氧基、乙氧基、羟基、氨基、乙酰氨基、甲磺酰氨基、溴、氯、氟、氰或氨基甲酰基取代的苯基均可作为强心药剂，相应的Ar为硝基苯基时可作为中间体。还显示了5-(Ar--CO)-6-[2-(二低碳基氨基)-乙烯基]-2(1H)-吡啶酮（II）或其盐作为中间体，其中Ar为苯基或甲基、乙基、甲氧基、乙氧基、溴、氯、氟、氰或硝基取代的苯基，以及5-(Ar--CO)-6-甲基-2(1H)-吡啶酮（III），其中Ar为苯基或甲基、乙基、甲氧基、乙氧基、溴、氯、氟、羟基、氰或硝基；当Ar为苯基或羟基苯基时，化合物（III）也可作为强心药剂。显示了制备式I、II和III化合物的方法。
• 1-6-Naphthyridin-2(1H)-ones useful as cardiotonics
  申请人：STERLING DRUG INC.

  公开号：EP0168037A2

  公开（公告）日：1986-01-15

  1-R-5-Ar-1,6-naphthyridin-2(1H)-ones (I) or salts thereof, where R is hydrogen or methyl, and Ar is phenyl or phenyl substituted by methyl, ethyl, methoxy, ethoxy, hydroxy, amino, acetylamino, methanesulfonylamino, bromo, chloro, fluoro, cyano or carbamyl are useful as cardiotonic agents and corresponding compounds where Ar is nitrophenyl are useful as intermediates. Also shown as intermediates, are 5-(Ar-CO)-6-[2-(di-lower-alkylamino)-ethenyl]-2(1H)-pyridinones (II) or salts thereof, where Ar is phenyl or phenyl substituted by methyl, ethyl, methoxy, ethoxy, bromo, chloro, fluoro, cyano or nitrp and 5-(Ar-CO)-6-methyl-2(1H)-pyridinones (III) where Ar is phenyl or phenyl substituted by methyl, ethyl, methoxy, ethoxy, bromo, chloro, fluoro, hydroxy, cyano or nitro; said compounds (III) where Ar is phenyl or hydroxyphenyl also are useful as cardiotonic agents. A process for preparing the compounds of formula I, comprises reacting compound (11) with formamidine or ammonia or a salt thereof.

  1-R-5-Ar-1,6-萘啶-2(1H)-酮(I)或其盐，其中 R 为氢或甲基，Ar 为苯基或被甲基、乙基、甲氧基、乙氧基、羟基、氨基、乙酰氨基、甲磺酰氨基、溴基、氯基、氟基、氰基或氨甲酰取代的苯基，可用作强心剂，Ar 为硝基苯基的相应化合物可用作中间体。作为中间体的还有 5-(Ar-CO)-6-[2-(二低烷基氨基)-乙烯基]-2(1H)-吡啶酮 (II) 或其盐，其中 Ar 是苯基或被甲基、乙基、甲氧基、乙氧基、溴基、氯基、氟基、氰基取代的苯基、和 5-(Ar-CO)-6-甲基-2(1H)-吡啶酮 (III)，其中 Ar 为苯基或被甲基、乙基、甲氧基、乙氧基、溴基、氯基、氟基、羟基、氰基或硝基取代的苯基；Ar 为苯基或羟基苯基的所述化合物（III）也可用作强心剂。制备式 I 化合物的工艺包括使化合物 (11) 与甲脒或氨或其盐反应。
• US4560691A
  申请人：——

  公开号：US4560691A

  公开（公告）日：1985-12-24
• Novel cAMP PDE III inhibitors: 1,6-naphthyridin-2(1H)-ones
  作者：Baldev Singh、George Y. Lesher、Kevin C. Pluncket、Edward D. Pagani、Donald C. Bode、Ross G. Bentley、Mary J. Connell、Linda T. Hamel、Paul J. Silver

  DOI：10.1021/jm00104a012

  日期：1992.12

  Two series of medorinone (3) analogs were prepared by modifications at C(2) and C(5). The C(2)-series was prepared from 2-chloro-5-methyl-1,6-naphthyridine (4) by replacement of the chloro group with various nucleophiles. The C(5)-series was prepared from 5-acyl-6-[2-(dimethylamino)ethenyl]-2-(1H)-pyridinone (11), 5-bromo-1,6-naphthyridin-2(1H)-one (17), and 1,3-diketones 19 and 27. 1,6-Naphthyridin-2(1H)-ones are novel inhibitors of cAMP PDE III. Modification of the carbonyl group of 3 or N-methylation at N(1) resulted in a dramatic loss of enzyme activity. Absence of the C(5)-methyl group of medorinone (3) or its shift to C(3) or C(7) also resulted in reduced activity. Substitution at C(3) also diminished activity. However, substitution at C(5) by a wide variety of substituents led to improvement of enzyme activity and several C(5)-substituted analogs were more potent than milrinone.
• Novel and Potent Adenosine 3',5'-Cyclic Phosphate Phosphodiesterase III Inhibitors: Thiazolo[4,5-b][1,6]naphthyridin-2-ones
  作者：Baldev Singh、Edward R. Bacon、George Y. Lesher、Shaughnessy Robinson、Patrick O. Pennock、Donald C. Bode、Edward D. Pagani、Ross G. Bentley、Mary J. Connell、Linda T. Hamel、Paul J. Silver

  DOI：10.1021/jm00014a007

  日期：1995.7

  The transformation of 3-bromo-1,6-naphthyridin-2(1H)-ones 8 to thiazolo[4,5-b][1,6]naphthyridin-2(1H)-ones 12 resulted in a 2-9-fold increase in cAMP phosphodiesterase (PDE) III inhibitory potency. Unlike the secondary binding sites on the cAMP PDE III isozyme which interact with the methyl group of milrinone (2) and CI-930 (4), the site which interacts with the 5-substituents of 1,6-naphthyridin-2(1H)-ones and the 8-substituents of thiazolo[4,5-b][1,6]-naphthyridin-2(1H)-ones 12 is able to accommodate a diverse group of substituents which have different steric and electronic requirements.